Efficacy and safety of more intensive lowering of LDL cholesterol

One-paragraph summary

The Cholesterol Treatment Trialists’ Collaboration meta-analyzed individual data from approximately 170,000 participants in 26 randomized statin trials. More-intensive therapy produced a further 15% reduction in major vascular events; across trials, each 1 mmol/L LDL-C reduction produced roughly 22% fewer major vascular events (CTT 2010, PMID 21067804).

Key findings

• Benefit tracked absolute LDL-C reduction.
• Relative effects were broadly consistent across baseline LDL strata.
• No cancer or nonvascular mortality signal offset benefit.

Limitations

• Predominantly statin comparisons; later non-statin trials extend the causal inference.
• Absolute benefit depends on baseline risk and duration.
• Very-low LDL exposure over decades was not tested.

Why it matters

The analysis supplies the field's quantitative LDL rule and the rationale for combination treatment when one drug cannot achieve sufficient reduction.

Cited by wiki pages

• Lipid lowering
• Overview
• Stable CAD management